Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis

AS Ismaila, EL Huisman, YS Punekar… - International journal of …, 2015 - Taylor & Francis
Background Randomized, controlled trials comparing long-acting muscarinic antagonist
(LAMA) efficacy in COPD are limited. This network meta-analysis (NMA) assessed the …

Comparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysis

EL Huisman, SM Cockle, AS Ismaila… - … Journal of Chronic …, 2015 - Taylor & Francis
Background Several new fixed-dose combination bronchodilators have been recently
launched, and assessing their efficacy relative to each other, and with open dual …

[HTML][HTML] A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting β2-Agonist (LABA) Combinations in COPD

KYJ Sion, EL Huisman, YS Punekar, I Naya… - Pulmonary …, 2017 - Springer
Introduction Comparative data on the efficacies of long-acting muscarinic antagonist (LAMA)
and long-acting β 2-agonist (LABA) combinations for the treatment of moderate-to-very …

Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands

B Hunt, SJP Malkin, RGJ Moes, EL Huisman… - BMJ Open Diabetes …, 2019 - drc.bmj.com
Objective Choosing therapies for type 2 diabetes that are both effective and cost-effective is
vital as healthcare systems worldwide aim to maximize health of the population. The present …

Evaluating the clinical and economic outcomes associated with poor glycemic control in people with type 1 diabetes in the netherlands

RGJ Moes, EL Huisman, SJP Malkin… - … and Outcomes Research, 2023 - Taylor & Francis
Introduction Achieving and maintaining glycemic control is the cornerstone of type 1
diabetes management, with the aim of reducing the incidence of diabetes-related …

[HTML][HTML] The long-term cost-effectiveness of oral semaglutide in the Netherlands based on the PIONEER 2, 3 and 4 randomized controlled trials

SJP Malkin, B Hunt, EL Huisman, TS Grand… - Diabetes Research and …, 2021 - Elsevier
Aims To assess the long-term cost-effectiveness of novel glucagon-like peptide-1 (GLP-1)
analog oral semaglutide versus sodium-glucose cotransporter-2 inhibitor empagliflozin …

Clinical effectiveness of liraglutide vs basal insulin in a real‐world setting: Evidence of improved glycaemic and weight control in obese people with type 2 diabetes

JA Overbeek, EM Heintjes, EL Huisman… - Diabetes, Obesity …, 2018 - Wiley Online Library
Aims To compare real‐world antidiabetic treatment outcomes over 12 months in obese
people with type 2 diabetes mellitus (T2DM) who previously received oral antidiabetic …

Economic evaluation of pooled solvent/detergent treated plasma versus single donor fresh-frozen plasma in patients receiving plasma transfusions in the United …

EL Huisman, SU de Silva, MA de Peuter - Transfusion and Apheresis …, 2014 - Elsevier
This study assessed the cost-effectiveness of Octaplas™ versus fresh frozen plasma (FFP)
in patients receiving plasma transfusions in the United States (US). Acute and long-term …

Cost-effectiveness and budget impact study of solvent/detergent (SD) treated plasma (octaplasLG®) versus fresh-frozen plasma (FFP) in any patient receiving …

EL Huisman, MC van Eerd, JNM Ouwens… - … and Apheresis Science, 2014 - Elsevier
The objectives of this study were to evaluate the cost-effectiveness and budget impact of
octaplasLG® compared with fresh-frozen plasma (FFP) in all patients receiving a transfusion …

[PDF][PDF] A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting b2-Agonist (LABA) Combinations in COPD

KYJSEL Huisman, YSPI Naya - 2017 - cyberleninka.org
Introduction: Comparative data on the efficacies of long-acting muscarinic antagonist
(LAMA) and long-acting b2-agonist (LABA) combinations for the treatment of moderate-to …